Pleural effusion
Last reviewed: May 2026
Outline
Pleural effusion affects 1.5 million patients in the United States annually, with the leading causes being heart failure (29%), malignancy (26%), pneumonia (16%), and pulmonary embolism. [1-2] A systematic and expeditious evaluation is essential, as delays in diagnosis (e.g., empyema) are associated with increased morbidity and mortality. [3]
1. History
- Onset and progression: Acute vs. insidious dyspnea; rate of symptom development correlates with speed of fluid accumulation rather than volume alone [1][4]
- Symptom characterization: Progressive dyspnea (most common), dry cough, pleuritic chest pain; patients may be entirely asymptomatic with small effusions [1]
- Key HPI questions:
- Orthopnea, PND, lower extremity edema → heart failure
- Fever, productive cough, rigors → parapneumonic/empyema
- Weight loss, night sweats, smoking history → malignancy or TB
- Recent surgery, immobilization, DVT symptoms → PE
- Alcohol use, jaundice, abdominal distension → cirrhosis/hepatic hydrothorax
- Medication changes (see Medications section)
- Important negatives: Absence of hemoptysis, trauma history, chest wall pain, joint symptoms, asbestos exposure [5]
2. Alarm Features
- Hemodynamic instability: Hypotension from massive effusion causing cardiac tamponade physiology (transmitted intrapleural pressure compressing the heart) [6]
- Respiratory failure: Severe hypoxia, tachypnea, accessory muscle use
- Empyema indicators: High fever, toxic appearance, purulent sputum with concurrent effusion; pH <7.2 or frank pus on aspiration mandates urgent drainage [1][7]
- Esophageal rupture (Boerhaave syndrome): Sudden chest pain after vomiting with subcutaneous emphysema — surgical emergency [1]
- Hemothorax: Pleural hematocrit >50% of peripheral hematocrit; requires urgent surgical consultation [1]
- Massive unilateral effusion with mediastinal shift: Suggests malignancy or large parapneumonic collection; risk of contralateral lung compression
- Tension hydrothorax: Rare but can cause obstructive shock physiology similar to tension pneumothorax
3. Medications
Medications that cause pleural effusion: [1][3][8]
- Common culprits: Amiodarone, dasatinib (~20% incidence), methotrexate, nitrofurantoin, phenytoin, clozapine, β-blockers, ergot alkaloids, valproic acid
- Immune checkpoint inhibitors: Pleural effusion reported as an immune-related adverse event in ~22% of serositis cases [9]
- Tyrosine kinase inhibitors: Dasatinib is the most notable; once-daily dosing reduces incidence vs. twice-daily [10]
- Drug-induced lupus: Hydralazine, procainamide, isoniazid — can cause exudative effusion with positive ANA/anti-histone antibodies
Treatment medications (see Treatment Plan section)
- Diuretics for transudative effusions
- Antibiotics (including anaerobic coverage with metronidazole) for complicated parapneumonic effusions [1]
- tPA/DNase for loculated infected effusions [1]
Caution: Pleural fluid eosinophilia should raise suspicion for drug-induced etiology; a detailed medication history is essential before pursuing extensive diagnostic workup [11]
4. Diet
- Sodium restriction: Critical in heart failure and cirrhotic effusions to optimize diuresis
- Fluid restriction: Typically 1.5–2 L/day in decompensated heart failure
- Alcohol cessation: Essential in cirrhotic hepatic hydrothorax
- Nutritional support: Important in empyema and malignant effusions; hypoalbuminemia (<1.5 g/dL) itself can cause transudative effusions [3]
- Protein supplementation: Consider in nephrotic syndrome and chronic illness with hypoalbuminemia
5. Review of Systems
- Pulmonary: Dyspnea, cough, hemoptysis, pleuritic chest pain
- Cardiac: Orthopnea, PND, leg swelling, palpitations
- Constitutional: Fever, night sweats, weight loss (malignancy, TB, empyema)
- GI: Abdominal distension/ascites (cirrhosis), dysphagia/vomiting (esophageal rupture), epigastric pain (pancreatitis)
- MSK/Rheumatologic: Joint pain, rash, oral ulcers (SLE, RA)
- GU: Foamy urine, periorbital edema (nephrotic syndrome)
- Hematologic: Easy bruising, lymphadenopathy (lymphoma)
- Gynecologic: Menstrual history (catamenial effusion), ovarian symptoms (Meigs syndrome, ovarian hyperstimulation)
6. Collateral History and Family History
- Collateral: Occupational exposures (asbestos → mesothelioma, benign asbestos effusion), travel history (TB-endemic areas), IV drug use (septic emboli), recent procedures/surgery [2]
- Family history: Malignancy (lung, breast, lymphoma), autoimmune disease (SLE, RA), familial Mediterranean fever, alpha-1 antitrypsin deficiency (cirrhosis)
- Social context: Alcohol use (cirrhosis), smoking (lung cancer, COPD), immunosuppression (HIV → TB, Kaposi sarcoma)
7. Risk Factors
- Heart failure: Most common cause overall; bilateral effusions, right > left [2-3]
- Pneumonia: 20–40% of hospitalized pneumonia patients develop parapneumonic effusion; up to 62% in ICU [1]
- Malignancy: Lung cancer is the most common cause of malignant effusion, followed by breast cancer and lymphoma [12]
- Cirrhosis/liver disease: Hepatic hydrothorax, typically right-sided
- Chronic kidney disease/nephrotic syndrome: Hypoalbuminemia, fluid overload
- Autoimmune disease: SLE (lupus pleuritis), RA (rheumatoid effusion with very low glucose)
- Post-surgical: Especially post-CABG; prevalence ~6.6% requiring intervention [2]
- Asbestos exposure: Benign asbestos effusion or mesothelioma
- Immunosuppression: TB, fungal infections
8. Differential Diagnosis
The differential is organized by the transudate vs. exudate framework: [3]
Transudative (systemic process)
- Congestive heart failure (>80% of transudates)
- Hepatic cirrhosis / hepatic hydrothorax
- Nephrotic syndrome
- Peritoneal dialysis
- Hypoalbuminemia
- Atelectasis, myxedema, SVC obstruction, trapped lung
Exudative (local/inflammatory process)
- Parapneumonic effusion / empyema (most common exudate)
- Malignancy (lung, breast, lymphoma, mesothelioma)
- Pulmonary embolism (can be transudate or exudate)
- Tuberculosis
- Autoimmune (SLE, RA)
- Pancreatitis, esophageal rupture
- Drug-induced
- Chylothorax (thoracic duct injury, lymphoma)
- Post-cardiac injury syndrome (Dressler syndrome)
Cannot-miss diagnoses
- Empyema — delay increases mortality
- Hemothorax — trauma, iatrogenic, coagulopathy
- Esophageal rupture — surgical emergency
- Pulmonary embolism — can present with effusion alone
- Malignancy — especially in unilateral, rapidly recurring effusions
Note: Multiple etiologies may coexist in up to 30% of pleural effusions. [2]
9. Past Medical History
- Heart failure, cirrhosis, CKD/nephrotic syndrome: Most common transudative causes
- Prior malignancy: Especially lung, breast, lymphoma — recurrence with malignant effusion
- Prior TB or TB exposure: Lymphocytic exudate with high ADA
- Autoimmune disease: SLE, RA
- Prior thoracic surgery or CABG: Post-surgical effusions common [2]
- Prior pleural effusion episodes: Recurrence pattern helps narrow etiology
- Asbestos exposure history: Latency period can be decades
- Coagulopathy or anticoagulant use: Risk of hemothorax
10. Physical Exam
Classic triad over the effusion: [13-14]
- Dullness to percussion — most accurate sign (positive LR 8.7) [13]
- Decreased/absent breath sounds
- Decreased tactile fremitus — absence makes effusion less likely (negative LR 0.21) [13]
Additional findings
- Asymmetric chest expansion (positive LR 8.1) [13]
- Decreased vocal resonance, egophony at the superior border of the effusion
- Tracheal deviation away from the effusion (massive effusion)
- Pleural friction rub (early or resolving effusion)
Systemic clues: [14]
- JVD, S3 gallop, peripheral edema → heart failure
- Ascites, spider angiomata, jaundice → cirrhosis
- Lymphadenopathy, cachexia → malignancy
- Joint swelling, malar rash → SLE
- Unilateral leg swelling → DVT/PE
Pearl: Physical exam has a lower positive likelihood ratio for detection compared to imaging; POCUS should be used early. [3][15]
11. Lab Studies
Serum labs (send concurrently with pleural fluid)
- CBC with differential, CMP, LDH, total protein, albumin
- NT-proBNP (>1500 pg/mL accurate for cardiac etiology without need for thoracentesis) [2-3]
- Coagulation studies (if thoracentesis planned)
- Blood cultures (if infection suspected)
Routine pleural fluid analysis (when thoracentesis performed): [1]
- Protein and LDH (with concurrent serum levels for Light's criteria)
- Cell count with differential
- Gram stain and culture (inoculate blood culture bottles at bedside)
- Cytology (send 50–60 mL if possible; 60% sensitivity for malignancy)
- pH (collect in ABG syringe; <7.2 = complicated parapneumonic effusion)
- Glucose
Light's Criteria — exudate if any one is met: [1][3]
- Pleural fluid protein / serum protein >0.5
- Pleural fluid LDH / serum LDH >0.6
- Pleural fluid LDH >2/3 upper limit of normal serum LDH
Sensitivity ~98% for exudates; specificity ~72% (25% of transudates misclassified, especially with diuretic use). [2] If heart failure suspected but Light's criteria suggest exudate, check serum-pleural albumin gradient >1.2 g/dL to reclassify as transudate. [2-3]
The following table summarizes additional pleural fluid tests based on clinical suspicion:
12. Imaging
Chest radiograph (first-line): [15]
- Detects >75 mL on lateral view, >175 mL on frontal view
- Blunting of costophrenic angle (earliest sign), meniscus sign, opacification of hemithorax
- Bilateral effusions with cardiomegaly suggest heart failure
Point-of-care ultrasound (POCUS) — strongly recommended: [1][3]
- Detects as little as >20 mL of fluid [15]
- Identifies septations, loculations, and pleural nodularity better than CT
- Guides thoracentesis (reduces complications including pneumothorax)
- Complex echogenic fluid suggests exudate; pleural nodularity has 97% specificity for malignancy [2]
CT chest with contrast: [2][15]
- Reference standard for imaging (detects >10 mL)
- Evaluates underlying parenchyma, mediastinum, pleural thickening/nodularity
- Loculations, thickened parietal pleura suggest complicated parapneumonic or malignant effusion
- Indicated when etiology unclear, malignancy suspected, or complex effusion
When imaging is unnecessary: Small bilateral effusions in known decompensated heart failure responding to diuresis do not require further imaging beyond CXR [1]
The following figure from the NEJM illustrates a management algorithm for parapneumonic effusions:
13. Special Tests
Diagnostic scoring
- Light's criteria — cornerstone for transudate vs. exudate differentiation [1]
- Porcel clinical scoring model — score ≥7 identifies cardiac etiology with 92% accuracy when Light's criteria suggest exudate [2]
Point-of-care tests
- Bedside POCUS — real-time assessment of effusion size, complexity, and procedural guidance [3]
- Pleural fluid pH — most accurate predictor for need for chest tube drainage in parapneumonic effusions; pH <7.2 = complicated [7]
Specialty tests
- Pleural ADA (adenosine deaminase): 91% sensitive, 88% specific for TB pleuritis [1]
- Pleural IGRA: 95% sensitive, 96% specific for TB [1]
- Pleural fluid triglycerides >110 mg/dL: Diagnostic for chylothorax [1]
- Pleural fluid cholesterol >250 mg/dL: Pseudochylothorax [1]
- Pleural biopsy (CT-guided or thoracoscopic): Indicated when cytology negative but malignancy or TB suspected; thoracoscopy diagnostic in 90% of cytology-negative malignant effusions [1]
14. ECG
- Sinus tachycardia: Most common ECG finding with large effusions [16]
- Low-voltage QRS complexes: Due to fluid insulating the heart from chest wall electrodes [16]
- Electrical alternans: Rare; more associated with pericardial effusion but can occur with massive pleural effusion causing cardiac swinging [16]
- Extreme QRS axis deviation: Reported to mimic acute MI patterns; resolves after thoracentesis [17]
- Indications for ECG: All patients with new pleural effusion to evaluate for heart failure, PE, pericarditis, or arrhythmia as contributing etiology
- Pearl: Large left-sided effusions can cause cardiac tamponade physiology with left ventricular diastolic collapse on echo, even without pericardial effusion [6][18]
15. Assessment
Severity stratification
- Small: Blunting of costophrenic angle only; <10 mm on ultrasound — often observation
- Moderate: Opacification of lower 1/3 of hemithorax
- Large/massive: >1/2 hemithorax; risk of respiratory compromise and hemodynamic effects
Typical presentation: Insidious dyspnea with dullness to percussion; often incidental on imaging [1]
Atypical presentations
- Elderly with empyema may present only with fatigue, weight loss, and failure to thrive [1]
- PE-associated effusion may be small and overlooked
- Hepatic hydrothorax can occur without clinically apparent ascites
Complications
- Empyema (progression from simple to complicated parapneumonic effusion) [19]
- Trapped/entrapped lung
- Fibrothorax from chronic inflammation
- Re-expansion pulmonary edema (after rapid large-volume drainage)
- Cardiac tamponade physiology from massive effusion [6]
16. Treatment Plan
Initial stabilization
- Supplemental O₂, positioning (upright), IV access
- Hemodynamic support if tamponade physiology present
Transudative effusions — treat the underlying cause: [2]
- Heart failure: Diuresis (furosemide), sodium/fluid restriction, guideline-directed medical therapy
- Cirrhosis: Diuretics (spironolactone + furosemide), sodium restriction, TIPS if refractory [20]
- Nephrotic syndrome: Diuretics, treat underlying glomerular disease
- Therapeutic thoracentesis for symptomatic relief if refractory; limit to 1–1.5 L per session to avoid re-expansion pulmonary edema
Exudative effusions — etiology-specific: [1]
- Simple parapneumonic: Antibiotics alone; monitor for progression
- Complicated parapneumonic (pH <7.2, glucose <40, positive Gram stain/culture): Chest tube drainage (small-bore 14–16 Fr) + antibiotics with anaerobic coverage (metronidazole) [7][20]
- Empyema (frank pus): Urgent chest tube drainage; consider tPA 10 mg + DNase 5 mg instilled via chest tube if loculated [1][19]
- Failure of medical management: VATS (video-assisted thoracoscopic surgery) for decortication; ~30% of patients may require surgical intervention [1]
- Malignant effusion: Therapeutic thoracentesis for symptom relief; for recurrent effusions, indwelling pleural catheter (IPC) or talc pleurodesis [12][20]
- TB pleuritis: Standard anti-TB therapy
17. Disposition
Admission criteria
- Complicated parapneumonic effusion or empyema requiring drainage
- Large effusion with respiratory distress or hemodynamic compromise
- New effusion with suspected malignancy requiring expedited workup
- Effusion in setting of sepsis or hemodynamic instability
- Need for chest tube placement
Observation indications
- Moderate effusion with stable vitals awaiting thoracentesis results
- Heart failure exacerbation with effusion responding to diuresis
Discharge criteria
- Small, asymptomatic transudative effusion with clear etiology (e.g., stable heart failure)
- Simple parapneumonic effusion with reliable follow-up and oral antibiotics
- Post-thoracentesis with no pneumothorax and symptom improvement
Specialist consultation triggers
- Pulmonology/interventional pulmonology: Complicated or loculated effusion, recurrent effusion, need for thoracoscopy or IPC [3]
- Thoracic surgery: Failed medical management, empyema requiring decortication
- Oncology: Confirmed or suspected malignant effusion
- Interventional radiology: Loculated effusion not amenable to bedside drainage
18. Follow Up / Return Precautions
Follow-up timing
- Post-thoracentesis: Repeat CXR within 24 hours (or sooner if symptomatic) to rule out pneumothorax
- Simple parapneumonic effusion on antibiotics: Reassess clinically and with imaging in 1–2 weeks [1]
- Undiagnosed exudative effusion: Follow-up within 1–2 weeks with pulmonology for possible repeat thoracentesis, biopsy, or thoracoscopy
- Malignant effusion: Ongoing palliative management with IPC or pleurodesis planning
Return precautions — instruct patients to return immediately for:
- Worsening shortness of breath or new chest pain
- Fever, chills, or rigors (especially post-procedure)
- Sudden sharp chest pain with dyspnea (pneumothorax)
- Hemoptysis or coughing up blood-tinged sputum
- Lightheadedness, syncope, or signs of hemodynamic compromise
Patient counseling
- Effusions often recur if the underlying cause is not addressed
- Importance of medication adherence (diuretics, antibiotics, anti-TB therapy)
- Smoking cessation if applicable
- Expected recovery: Simple effusions resolve in days to weeks with treatment; complicated effusions may require prolonged drainage and weeks of antibiotics [19]
References
- 1.Shen-Wagner J, Gamble C, MacGilvray P. Pleural Effusion: Diagnostic Approach in Adults. American Family Physician. 2023. Link
- 2.Shen-Wagner J, Gamble C, MacGilvray P. Pleural Effusion: Diagnostic Approach in Adults. American Family Physician. 2023. Link
- 3.Shen-Wagner J, Gamble C, MacGilvray P. Pleural Effusion: Diagnostic Approach in Adults. American Family Physician. 2023. Link
- 4.Sundaralingam A, Grabczak EM, Burra P, et al. ERS Statement on Benign Pleural Effusions in Adults. The European Respiratory Journal. 2024. Link
- 5.Sundaralingam A, Grabczak EM, Burra P, et al. ERS Statement on Benign Pleural Effusions in Adults. The European Respiratory Journal. 2024. Link
- 6.Feller-Kopman D, Light R. Pleural Disease. The New England Journal of Medicine. 2018. Link
- 7.Feller-Kopman D, Light R. Pleural Disease. The New England Journal of Medicine. 2018. Link
- 8.Saguil A, Wyrick K, Hallgren J. Diagnostic Approach to Pleural Effusion. American Family Physician. 2014. Link
- 9.Saguil A, Wyrick K, Hallgren J. Diagnostic Approach to Pleural Effusion. American Family Physician. 2014. Link
- 10.Chopra A, Hu K, Judson MA, Feller-Kopman D. Clinical Approach to a Pleural Effusion. Chest. 2025. Link
- 11.Chopra A, Hu K, Judson MA, Feller-Kopman D. Clinical Approach to a Pleural Effusion. Chest. 2025. Link
- 12.Kaplan LM, Epstein SK, Schwartz SL, Cao QL, Pandian NG. Clinical, Echocardiographic, and Hemodynamic Evidence of Cardiac Tamponade Caused by Large Pleural Effusions. American Journal of Respiratory and Critical Care Medicine. 1995. Link
- 13.Kaplan LM, Epstein SK, Schwartz SL, Cao QL, Pandian NG. Clinical, Echocardiographic, and Hemodynamic Evidence of Cardiac Tamponade Caused by Large Pleural Effusions. American Journal of Respiratory and Critical Care Medicine. 1995. Link
- 14.Bedawi EO, Ricciardi S, Hassan M, et al. ERS/ESTS Statement on the Management of Pleural Infection in Adults. The European Respiratory Journal. 2023. Link
- 15.Bedawi EO, Ricciardi S, Hassan M, et al. ERS/ESTS Statement on the Management of Pleural Infection in Adults. The European Respiratory Journal. 2023. Link
- 16.Morelock SY, Sahn SA. Drugs and the Pleura. Chest. 1999. Link
- 17.Morelock SY, Sahn SA. Drugs and the Pleura. Chest. 1999. Link
- 18.Elias E, Rohs N, Koseki M, et al. Edema and serositis as an adverse event in patients with cancer receiving immune checkpoint blockade: Systematic review to evaluate this immune-related adverse event and associated treatment strategie. Journal of Clinical Oncology. 2023. Link
- 19.Elias E, Rohs N, Koseki M, et al. Edema and serositis as an adverse event in patients with cancer receiving immune checkpoint blockade: Systematic review to evaluate this immune-related adverse event and associated treatment strategie. Journal of Clinical Oncology. 2023. Link
- 20.Brixey AG, Light RW. Pleural Effusions Due to Dasatinib. Current Opinion in Pulmonary Medicine. 2010. Link
- 21.Brixey AG, Light RW. Pleural Effusions Due to Dasatinib. Current Opinion in Pulmonary Medicine. 2010. Link
- 22.Huggins JT, Sahn SA. Drug-Induced Pleural Disease. Clinics in Chest Medicine. 2004. Link
- 23.Huggins JT, Sahn SA. Drug-Induced Pleural Disease. Clinics in Chest Medicine. 2004. Link
- 24.Jany B, Welte T. Pleural Effusion in Adults-Etiology, Diagnosis, and Treatment. Deutsches Arzteblatt International. 2019. Link
- 25.Jany B, Welte T. Pleural Effusion in Adults-Etiology, Diagnosis, and Treatment. Deutsches Arzteblatt International. 2019. Link
- 26.Wong CL, Holroyd-Leduc J, Straus SE. Does This Patient Have a Pleural Effusion?. The Journal of the American Medical Association. 2009. Link
- 27.Wong CL, Holroyd-Leduc J, Straus SE. Does This Patient Have a Pleural Effusion?. The Journal of the American Medical Association. 2009. Link
- 28.Light RW. Pleural Effusion. The New England Journal of Medicine. 2002. Link
- 29.Light RW. Pleural Effusion. The New England Journal of Medicine. 2002. Link
- 30.Morris MF, Henry TS, Raptis CA, et al. ACR Appropriateness Criteria® Workup of Pleural Effusion or Pleural Disease. Journal of the American College of Radiology : JACR. 2024. Link
- 31.Morris MF, Henry TS, Raptis CA, et al. ACR Appropriateness Criteria® Workup of Pleural Effusion or Pleural Disease. Journal of the American College of Radiology : JACR. 2024. Link
- 32.Argula RG, Negi SI, Banchs J, Yusuf SW. Role of a 12‐Lead Electrocardiogram in the Diagnosis of Cardiac Tamponade as Diagnosed by Transthoracic Echocardiography in Patients With Malignant Pericardial Effusion. Clinical Cardiology. 2015. Link
- 33.Argula RG, Negi SI, Banchs J, Yusuf SW. Role of a 12‐Lead Electrocardiogram in the Diagnosis of Cardiac Tamponade as Diagnosed by Transthoracic Echocardiography in Patients With Malignant Pericardial Effusion. Clinical Cardiology. 2015. Link
- 34.Manthous CA, Schmidt GA, Hall JB. Pleural Effusion Masquerading as Myocardial Infarction. Chest. 1993. Link
- 35.Manthous CA, Schmidt GA, Hall JB. Pleural Effusion Masquerading as Myocardial Infarction. Chest. 1993. Link
- 36.Bilku RS, Bilku DK, Rosin MD, Been M. Left Ventricular Diastolic Collapse and Late Regional Cardiac Tamponade Postcardiac Surgery Caused by Large Left Pleural Effusion. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2008. Link
- 37.Bilku RS, Bilku DK, Rosin MD, Been M. Left Ventricular Diastolic Collapse and Late Regional Cardiac Tamponade Postcardiac Surgery Caused by Large Left Pleural Effusion. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2008. Link
- 38.Sorino C, Mondoni M, Lococo F, Marchetti G, Feller-Kopman D. Optimizing the Management of Complicated Pleural Effusion: From Intrapleural Agents to Surgery. Respiratory Medicine. 2022. Link
- 39.Sorino C, Mondoni M, Lococo F, Marchetti G, Feller-Kopman D. Optimizing the Management of Complicated Pleural Effusion: From Intrapleural Agents to Surgery. Respiratory Medicine. 2022. Link
- 40.Porcel JM. Nonmalignant Pleural Effusions. Seminars in Respiratory and Critical Care Medicine. 2022. Link
- 41.Porcel JM. Nonmalignant Pleural Effusions. Seminars in Respiratory and Critical Care Medicine. 2022. Link